Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Receivables (2020 - 2025)

Maxcyte (MXCT) has disclosed Receivables for 6 consecutive years, with $8.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 82.15% to $8.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.3 million, a 82.15% increase, with the full-year FY2024 number at $4.7 million, down 18.97% from a year prior.
  • Receivables was $8.3 million for Q3 2025 at Maxcyte, up from $5.8 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $11.2 million in Q4 2022 to a low of $4.6 million in Q3 2024.
  • A 5-year average of $6.8 million and a median of $6.4 million in 2021 define the central range for Receivables.
  • Peak YoY movement for Receivables: crashed 48.3% in 2023, then soared 82.15% in 2025.
  • Maxcyte's Receivables stood at $6.9 million in 2021, then skyrocketed by 62.5% to $11.2 million in 2022, then plummeted by 48.3% to $5.8 million in 2023, then fell by 18.97% to $4.7 million in 2024, then surged by 77.4% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Receivables are $8.3 million (Q3 2025), $5.8 million (Q2 2025), and $5.5 million (Q1 2025).